key: cord-0691425-6mli5sci
authors: Emeksiz, Serhat; Çelikel Acar, Banu; Kibar, Ayşe Esin; Özkaya Parlakay, Aslınur; Perk, Oktay; Bayhan, Gülsüm İclal; Cinel, Güzin; Özbek, Namık; Azılı, Müjdem Nur; Çelikel, Elif; Akça, Halise; Dibek Mısırlıoğlu, Emine; Bayrakçı, Umut Selda; Çetin, İbrahim İlker; Neşe Çıtak Kurt, Ayşegül; Boyraz, Mehmet; Hızlı, Şamil; Şenel, Emrah
title: Algorithm for the diagnosis and management of the multisystem inflammatory syndrome in children associated with COVID‐19
date: 2021-06-28
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14471
sha: 4c86aaa5fabe25a0d9208d3880eb254361d94672
doc_id: 691425
cord_uid: 6mli5sci

OBJECTIVE: Although the initial reports of COVID‐19 cases in children described that children were largely protected from severe manifestations, clusters of paediatric cases of severe systemic hyperinflammation and shock related to severe acute respiratory syndrome coronavirus 2 infection began to be reported in the latter half of April 2020. A novel syndrome called “multisystem inflammatory syndrome in children” (MIS‐C) shares common clinical features with other well‐defined syndromes, including Kawasaki disease, toxic shock syndrome and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Our objective was to develop a protocol for the evaluation, treatment and follow‐up of patients with MIS‐C. METHODS: The protocol was developed by a multidisciplinary team. We convened a multidisciplinary working group with representation from the departments of paediatric critical care, cardiology, rheumatology, surgery, gastroenterology, haematology, immunology, infectious disease and neurology. Our protocol and recommendations were based on the literature and our experiences with multisystem inflammatory syndrome in children. After an agreement was reached and the protocol was implemented, revisions were made on the basis of expert feedback. CONCLUSION: Children may experience acute cardiac decompensation or other organ system failure due to this severe inflammatory condition. Therefore, patients with severe symptoms of MIS‐C should be managed in a paediatric intensive care setting, as rapid clinical deterioration may occur. Therapeutic approaches for MIS‐C should be tailored depending on the patients’ phenotypes. Plasmapheresis may be useful as a standard treatment to control hypercytokinemia in cases of MIS‐C with severe symptoms. Long‐term follow‐up of patients with cardiac involvement is required to identify any sequelae of MIS‐C.

in Italy, the United Kingdom and the United States. [3] [4] [5] A novel syndrome in children termed "multisystem inflammatory syndrome in children" (MIS-C) associated with SARS-CoV-2 infection was described. The cluster of MIS-C cases lagged behind the peak incidence of COVID-19 among adults by approximately one month.

Positive SARS-CoV-2 serological test results has been reported in a greater proportion (80%-90%) of patients with MIS-C than positive polymerase chain reaction test results (20%-40%), which suggests that this syndrome may be post-infectious rather than related to acute early infection. Therefore, MIS-C is a delayed immunological phenomenon associated with hyperinflammation following symptomatic or asymptomatic COVID-19 infection. 4, 5 Although our understanding of COVID-19 in children has shown a remarkable advancement, deficiencies in data and approaches to MIS-C remain owing to the small number of MIS-C cases. Given the severity of MIS-C associated with COVID-19, there is an urgent need for awareness of MIS-C, so that key points in the diagnosis and follow-up of patients and optimal treatment strategies can be designed. We convened a multidisciplinary study group with representation from the departments of paediatric cardiology, rheumatology, critical care, infectious diseases, haematology, pulmonology, immunology, neurology, gastroenterology, nephrology and surgery.

The following proposed algorithms were created by the MIS-C Study Group at our centre. Recommendations were based on expert opinion with the experience with approximately 150 patients with MIS-C who were followed up at our centre. In addition, published studies from our centre that included MIS-C data were also included. Here, we present an overview of clinical and laboratory features and complications and propose a plan for the evaluation and management of patients with MIS-C on the basis of our experience and literature review. syndrome in children. After an agreement was reached and the protocol was implemented, revisions were made on the basis of expert feedback.

Conclusion: Children may experience acute cardiac decompensation or other organ system failure due to this severe inflammatory condition. Therefore, patients with severe symptoms of MIS-C should be managed in a paediatric intensive care setting, as rapid clinical deterioration may occur. Therapeutic approaches for MIS-C should be tailored depending on the patients' phenotypes. Plasmapheresis may be useful as a standard treatment to control hypercytokinemia in cases of MIS-C with severe symptoms. Long-term follow-up of patients with cardiac involvement is required to identify any sequelae of MIS-C.

• A comprehensive search strategy using text words and Medical Subject Heading (MeSH) was designed.

• We searched Scopus, PubMed, Embase, and Google Scholar for relevant trials published up to 10 April 2021 with related inclusion and exclusion criteria.

• This review was based on the literature and our experiences with the multisystem inflammatory syndrome in children.

• Early diagnosis and treatment are essential for MIS-C.

• TPE may be considered as a therapeutic option in children with severe MIS-C. | 3 of 9 EMEKSIZ Et al.

The protocol was developed by a multidisciplinary team. We convened a multidisciplinary working group. The objectives of our protocol included rapid detection of MIS-C cases, clinical presentation, reduction of the risk of coronary artery abnormalities and control of the hyperinflammatory state to cure or prevent shock and organ damage, and identification of patients suitable for undergoing plasmapheresis. Our protocol and recommendations were based on the literature and our experiences with MIS-C. After an agreement was reached and the protocol was implemented, revisions were made on the basis of expert feedback.

The World Health Organization and the Centers for Disease Control and Prevention issued case definitions for MIS-C. 6, 7 Although the criteria used for case definition vary between the two health agencies, both definitions require the presence of fever, elevated inflammatory markers, at least two signs of multisystem involvement, evidence of SARS-CoV-2 infection or exposure and exclusion of other potential causes (Table 1 ).

MIS-C related to SARS-CoV-2 has predominantly been reported in previously healthy children. Fever, severe abdominal pain, cardiac dysfunction, shock, ARDS, neurological changes, dehydration and features of KD may be present.

In the case series from Bergamo, Italy, KD and KD-like illnesses were observed at an incidence rate 30 times higher than that in the previous five years. 3 The emergence of clusters of KD and KD-like illnesses in areas that have been heavily affected by COVID-19, such as Italy, the United Kingdom and New York City, clearly suggests a link between SARS-CoV-2 and MIS-C. [3] [4] [5] However, only a quarter to around one-half of all reported MIS-C cases meet the full diagnostic criteria for KD. 8 

Cardiac involvement occurs in some patients with MIS-C, and long-term follow-up of these patients is required after discharge. All patients with MIS-C who meet the criteria for KD should be treated in accordance with the published guidelines for KD. 12 Firstline therapy for KD includes high-dose IVIG (2 g/day) and aspirin.

Cardiac function and fluid status should be evaluated before IVIG Steroids are widely used in the treatment of diseases with a hyperinflammatory state, such as MIS-C. 13 An exaggerated inflammatory response that leads to MIS-C after SARS-CoV-2 infection has been described, although it can occur to a lesser degree with other viral infections. 14 As rapid identification and treatment of MIS-C may be more important than the specific type of biological agent, paediatricians should be careful to diagnose possible cases, especially in the period after the peak of the incidence of COVID-19.

Of the 35 documented papers related to MIS-C cases, the characteristics of 783 cases were evaluated. Twelve patients (1.5%)

were reported to have died; the cause of death was not stated for most patients, but two died after a stroke, and seven died despite extracorporeal membrane oxygenation, although the cause of each death is not known. 26 The mortality risk is higher in patients with severe MIS-C. We think that therapeutic plasma exchange (TPE) may be useful as an initial therapy, especially in patients with se- Table 2 ). The management of children with abnormal coronary arteries, documented thrombosis, or an ejection fraction < 35% should be discussed with a haematologist regarding the use of long-term antiplatelet and anticoagulation therapies. 19 Recommendations for hospital discharge are influenced by the many events that occur with the patient's clinical condition at the time of discharge (Table 2) .

MIS-C is a life-threatening hyperinflammatory syndrome that mainly damages multiple-organ systems predominantly in previously healthy children during the COVID-19 pandemic. TPE may be useful as an initial therapy, especially in patients with severe manifestations. Larger multicentre studies are needed to elucidate the spectrum of diseases, risk factors of more severe disease and treatment strategies. The long-term implications of the cardiac involvement in MIS-C are unknown but may be important as in KD.

Long-term follow-up of patients with MIS-C is required, especially in terms of cardiac effects.

The authors have no conflicts of interest to declare.

Algorithms were created following the CDC case definition/WHO case definition with input from specialists in the areas of pediatric infectious diseases, pediatric intensive care unit, pediatric cardiology, pediatric rheumatology, pediatric hematology, pediatric pulmonology, pediatric emergency medicine, pediatric neurology, pediatric nephrology, pediatric allergy/immunology, gastroenterology, pediatric endocrinology and metabolism, pediatric gastroenterology and pediatric surgery. The MIS-C Study Group comprised 18 participants TA B L E 2 Hospital discharge planning of patients with multisystem inflammatory syndrome associated with COVID-19 in children 1 . Antiplatelet and anticoagulation therapy in MIS-C: a. Low dose aspirin (3-5 mg/kg/day) should be used in patients with KD-like features and/or thrombocytosis (platelet count ≥450 000/μL) and continued until normalisation of platelet count and confirmed normal coronary arteries at ≥4 weeks after diagnosis b. Longer outpatient therapeutic LMWH management should be tailored to the patient by haematologists c. Patients with MIS-C and documented LV dysfunction should receive LMWH until at least 2 weeks after discharge from the hospital d. Patients with MIS-C and CAA, documented thrombosis, or ongoing moderate to severe LV dysfunction should receive LMWH until at least ≥3 months after discharge from the hospital 2. Outpatient cardiology, infectious diseases, rheumatology/ immunology follow-up should be 1 to 2 weeks after discharge 3. Families should be informed about to admit to the emergency department in case of palpitation, chest pain, dyspnoea, presyncope or syncope 4. Patients with ventricular dysfunction should have cardiac MRI and 24-hour Holter monitoring 2-6 months later 5. Exercise should be restricted for 2 weeks in patients without cardiac involvement and at least 6 months in patients with myocarditis

Abbreviations: CAA, coronary artery aneurysm; KD, Kawasaki disease; LMWH, low-molecular-weight heparin; LV, left ventricular, MIS-C, multisystem inflammatory syndrome in children; MRI: magnetic resonance imaging.

including: Serhat Emeksiz, Banu Çelikel Acar, Ayşe Esin Kibar, Aslınur

SARS-CoV-2 infections in children and young people

A novel coronavirus from patients with pneumonia in China

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City

Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)

syste m-infla mmato rysyn drome -in-child ren-and-adole scent s-with-covid -19

Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management

A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process

Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children

Multisystem inflammatory syndrome in children: survey of protocols for early hospital evaluation and management

Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young

Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up

Viral etiology, clinical and laboratory features of adult hemophagocytic lymphohistiocytosis

COVID-19 cytokine storm: The interplay between inflammation and coagulation

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Corticosteroids for the treatment of Kawasaki disease in children

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease-the SHARE initiative

American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1

Favorable Anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Effective treatment of severe COVID-19 patients with tocilizumab

Role of biological agents in the treatment of SARS-CoV-2-associated multisystem inflammatory syndrome in children

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab

Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation

Turkish secondary HLH/ MAS critical care study group. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/ multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab. Zhejiang Da Xue Bao Yi Xue Ban

Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases

Therapeutic plasma exchange as a rescue therapy in patients with coronavirusdisease 2019: a case series

Therapeutic plasma exchange: a potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit

Algorithm for the diagnosis and management of the multisystem inflammatory syndrome in children associated with COVID-19